Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
AstraZeneca
McKesson
US Army
Chubb
Medtronic
Cipla
Citi

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,220,424

« Back to Dashboard

Which drugs does patent 7,220,424 protect, and when does it expire?

Patent 7,220,424 protects VANOS and is included in one NDA.

This patent has eleven patent family members in nine countries.
Summary for Patent: 7,220,424
Title:Compositions and methods for enhancing corticosteroid delivery
Abstract:The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
Inventor(s): Gans; Eugene H. (Westport, CT), Wortzman; Mitchell S. (Scottsdale, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:10/407,380
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 7,220,424

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medicis VANOS fluocinonide CREAM;TOPICAL 021758-001 Feb 11, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,220,424

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,771,733 Compositions and methods for enhancing corticosteroid delivery ➤ Try a Free Trial
7,794,738 Compositions and methods for enhancing corticosteroid delivery ➤ Try a Free Trial
8,232,264 Compositions and methods for enhancing corticosteroid delivery ➤ Try a Free Trial
6,765,001 Compositions and methods for enhancing corticosteroid delivery ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,220,424

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002360589 ➤ Try a Free Trial
Brazil 0215254 ➤ Try a Free Trial
Canada 2471041 ➤ Try a Free Trial
China 1617730 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Federal Trade Commission
Healthtrust
Deloitte
Fish and Richardson
Queensland Health
Julphar
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.